The US Food and Drug Administration relaxed notification requirements on some device modifications in May 2020 to ensure a consistent supply of devices during a time of widespread shortages. But two and a half years later, the agency now says this enforcement discretion will continue indefinitely.
That is one of the messages in a 30 October final guidance document, “Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?